Digital Marketing & Social Media in Pharma Reviewed in New Study Published at MarketPublishers.com

Share Article

Today, digital channels offer life science companies enormous untapped opportunities to reach and interwork with physicians and patients. New research study “Pharmaceutical Digital Marketing and Social Media” worked out by Cutting Edge Information has been recently published by Market Publishers Ltd.

marketpublishers.com

Market Publishers Ltd

Today, digital channels offer life science companies enormous untapped opportunities to reach and interwork with physicians and patients. Some marketing teams have already responded by boosting their digital activity, with growth trends indicating that some digital channels will surpass more traditional media tools.

However, a host of challenges faced by the industry like regulatory compliance, ROI, adverse events monitoring, etc. leave companies behind the curve as they try to navigate both opportunities and hidden dangers. Meanwhile, leading-edge firms forge ahead by integrating digital tools into overall brand - and corporate-level strategies.

New research study “Pharmaceutical Digital Marketing and Social Media” worked out by Cutting Edge Information has been recently published by Market Publishers Ltd.

Report Details:

Title: Pharmaceutical Digital Marketing and Social Media
Published: December, 2011
Pages: 187
Price: US$ 7,695.00
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/pharmaceutical_digital_marketing_n_social_media.html

The report is a must-have for those who want to:

  •     explore real-world marketing mixes, case studies and rankings to understand industry-wide usage and goals for digital marketing, social media and mobile technology;
  •     learn how leading companies manage compliance, gauge ROI and avoid outsourcing pitfalls; as well as explore how digital models help teams mitigate regulatory risks and earn internal buy-in for new initiatives.;
  •     benchmark structure, staffing, budget and reporting lines to develop a team equipped to face challenges both now and in the future.

Report Contents:

Executive Summary

Study Methodology
Study DeUnitions
Digital Marketing: Key Findings and Recommendations

Integrating Digital and Traditional Channels

The New Pharmaceutical Marketing Mix

Social Media and Mobile Technology in Pharma

Pharma’s In-Roads into Social Media
Mobile Technology
eMarketing Structure, Stafung and Budgets
eMarketing Organizational Structure
eMarketing StafUng Resources
Digital Marketing Budgets

Outsourcing Digital Marketing

Agency Ratings: Six Categories for Digital Success

Structural Strategies for Mitigating Digital Marketing Risk

Charts and Graphics

Executive Summary
Figure E.1: Digital and Traditional Channels as a Percentage of the Overall 2011 Marketing Media Mix
Figure E.2: Media Mix for All Companies from 2009-2011
Digital Marketing: Key Findings and Recommendations
Figure E.3: Percentage Change in Media Mix from 2009 to 2011
Figure E.4: Dedicated eMarketing Groups’ Staffing (FTEs)
Figure E.5: Total eMarketing Budgets
Figure E.6: Brand-Level eMarketing Spending During Registration & Launch
Figure E.7: Percentage of Companies Engaged in At Least One Type of Social Media Activity
Figure E.8: Ratings of Challenges to Social Media Adoption
Figure E.9: Effect of Lack of FDA Guidance on Companies’ DTC Social Media Strategy
Figure E.10: Overall Opinion of Contract Agency’s Ability to Carry Out Pharmaceutical Digital Marketing
Integrating Digital and Traditional Channels
Figure 1.1: Age of Dedicated eMarketing Groups
The New Pharmaceutical Marketing Mix
Figure 1.2: Media Mix for All Companies from 2009-2011
Figure 1.3: Percentage Change in Media Mix from 2009 to 2011
Figure 1.4: Media Mix for Top 10 Companies from 2009-2011
Figure 1.5: Media Mix for Top 50 Companies from 2009-2011
Figure 1.6: Media Mix for Top 100 Companies from 2009-2011
Figure 1.7: Media Mix for US Companies from 2009-2011
Figure 1.8: Media Mix for Non-US Companies from 2009-2011
Figure 1.9: Media Mix for Brand-level Groups from 2009-2011
Figure 1.10: Media Mix for Corporate-level Groups from 2009-2011
Social Media and Mobile Technology in Pharma
Pharma’s In-Roads into Social Media
Figure 2.1: Percentage of Companies Engaged in At Least One Type of Social Media Activity
Figure 2.2: Number of Companies Engaged in Each Type of Social Media Activity
Figure 2.3: Companies Engaged in Each Type of Social Media Activity, by Percentage
Figure 2.4: Companies Engaged in Each Type of Social Media Activity at Corporate and Brand Levels
Figure 2.5: Ratings of Positive Impact Potential of Social Media, by Activity Type
Figure 2.6: Ratings Spread of Positive Impact Potential of Social Media, by Activity Type
Figure 2.7: Ratings of Challenges to Social Media Adoption
Figure 2.8: Ratings Spread of Challenges to Social Media Adoption
Figure 2.9: How Companies Measure Social Media Initiatives
Figure 2.10: Effect of Lack of FDA Guidance on Companies’ DTC Social Media Strategy
Figure 2.11: Effect of Lack of FDA Guidance on Companies’ DTC Social Media Strategy (US vs Non-US)
Figure 2.12: Support for Regulatory and Non-Regulatory Options
Figure 2.13: Ratings of Marketing Potential of Online Channels
Figure 2.14: Employee Use of Social Media and Formal Policies
Mobile Technology
Figure 2.15: Percentage of Brands Using Mobile Technology for Marketing or Medical Affairs Initiatives
...

More new studies by the publisher can be found at Cutting Edge Information page.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website